Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.046
Sell
RSI(14)
46.981
Neutral
STOCH(KDJ)(9,3,3)
48.282
Sell
ATR(14)
3.158
Low Volatility
CCI(14)
-20.757
Neutral
Williams %R
67.634
Sell
TRIX(12,20)
-0.194
Sell
StochRSI(14)
0.000
Sell
Twist Bioscience Corp
TWST44.530USD
-2.220-4.75%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.18BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Twist Bioscience Corp
Currency: USD Updated: 2026-03-27Key Insights
Twist Bioscience Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.60.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Twist Bioscience Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Twist Bioscience Corp Highlights
StrengthsRisks
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.63% year-on-year.
Undervalued
The company’s latest PE is -35.23, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.72M shares, decreasing 4.29% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.76M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.78.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
50.600
Target Price
+6.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Twist Bioscience Corp is 7.67, ranking 95 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 103.70M, representing a year-over-year increase of 16.89%, while its net profit experienced a year-over-year increase of 3.44%.
Score
Financials
7.64
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
8.95
Growth Potential
6.95
Shareholder Returns
7.19
Twist Bioscience Corp's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Twist Bioscience Corp is 7.58, ranking 61 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -35.23, which is -91.35% below the recent high of -3.05 and -23.33% above the recent low of -43.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 30/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Twist Bioscience Corp is 8.55, ranking 26 out of 157 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 57.17 and a low of 32.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
50.600
Target Price
+8.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Twist Bioscience Corp
TWST
11
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Twist Bioscience Corp is 7.11, ranking 38 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 49.73 and the support level at 40.43, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
46.382
Sell
MA10
45.553
Sell
MA20
45.931
Sell
MA50
46.313
Sell
MA100
39.123
Buy
MA200
35.195
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Twist Bioscience Corp is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 120.24%, representing a quarter-over-quarter increase of 0.97%. The largest institutional shareholder is Catherine Wood, holding a total of 7.56M shares, representing 12.33% of shares outstanding, with 18.36% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Artisan Partners Limited Partnership
William Blair Investment Management, LLC
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Amova Asset Management Co., Ltd.
Soleus Capital Management, L.P.
Goldman Sachs & Company, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Twist Bioscience Corp is 4.71, ranking 83 out of 157 in the Pharmaceuticals industry. The company's beta value is 2.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.23
VaR
+7.21%
240-Day Maximum Drawdown
+39.86%
240-Day Volatility
+70.04%
Return
Best Daily Return
60 days
+13.98%
120 days
+16.26%
5 years
+28.74%
Worst Daily Return
60 days
-8.19%
120 days
-10.13%
5 years
-19.92%
Sharpe Ratio
60 days
+2.17
120 days
+1.45
5 years
+0.13
Risk Assessment
Maximum Drawdown
240 days
+39.86%
3 years
+58.97%
5 years
+91.54%
Return-to-Drawdown Ratio
240 days
+0.37
3 years
+1.54
5 years
-0.13
Skewness
240 days
+0.22
3 years
+0.83
5 years
+0.40
Volatility
Realised Volatility
240 days
+70.04%
5 years
+79.86%
Standardised True Range
240 days
+4.94%
5 years
+6.71%
Downside Risk-Adjusted Return
120 days
+279.86%
240 days
+279.86%
Maximum Daily Upside Volatility
60 days
+59.46%
Maximum Daily Downside Volatility
60 days
+48.27%
Liquidity
Average Turnover Rate
60 days
+2.20%
120 days
+2.12%
5 years
--
Turnover Deviation
20 days
+78.44%
60 days
+21.90%
120 days
+17.81%
Peer Comparison
Pharmaceuticals
Twist Bioscience Corp
TWST
7.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
